Protocol Ledger

Federal / Public Agency · Consolidated Sponsor Hub

National Institute of Allergy and Infectious Diseases (NIAID): Clinical Trials & FDA Approval Profile

National Institute of Allergy and Infectious Diseases (NIAID) (Global / Institutional) sponsors 185 reconciled interventional Phase II and Phase III ClinicalTrials.gov studies (2018 to 2026), including 54 active protocols (43 recruiting now), 99 completed protocols, and 0 all-time original FDA Drugs@FDA NDA and BLA approvals.

Track in Studio / Generate Client Brief ->
Early-Stop Rate vs National (13.8%)17.3%
Median Closed Enrollment vs National (145 pts)94 participants

Verified Sponsor Execution & Regulatory Ledger

Reconciled ClinicalTrials.gov v2 & Drugs@FDA Metrics for National Institute of Allergy and Infectious Diseases (NIAID)
Sponsor MetricVerified Count / Rate
Phase II & III Protocols (2018 to 2026)185
Active Pipeline (Recruiting Now)54 (43)
Completed vs Stopped Early99 / 32 (17.3%)
Median Closed Actual Enrollment94 participants
Physical Hospital Site Disclosure97.7% named hospitals
FDA Drugs@FDA Original NDA/BLA Approvals0 (0 since 2018)

Top Partner U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Partnered With National Institute of Allergy and Infectious Diseases (NIAID)
Hospital Research SiteLocationShared Protocols
UCLA Health and Jonsson Comprehensive Cancer CenterLos Angeles, CA41
UCSF Medical Center and Helen Diller Cancer CenterSan Francisco, CA40
Vanderbilt University Medical CenterNashville, TN38

Indexed Multi-Center Phase II & III Protocols

Representative ClinicalTrials.gov v2 Studies Sponsored by National Institute of Allergy and Infectious Diseases (NIAID)
NCT IdentifierProtocol Brief TitlePhaseStatus
NCT07015996Efficacy of Tezepelumab in Peanut Oral ImmunotherapyPhase IIRECRUITING
NCT06075745Cytomegalovirus (CMV) Vaccine in Orthotopic Liver Transplant CandidatesPhase IIRECRUITING
NCT06476132Belumosudil to Block Chronic Lung Allograft Dysfunction (CLAD) in High Risk Lung Transplant RecipientsPhase IIRECRUITING
NCT05201469VIBRANT: VIB4920 for Active Lupus NephritisPhase IIRECRUITING
NCT06280950Expanding Liver Transplant Immunosuppression Minimization Via EverolimusPhase IIRECRUITING

Explore interactive annual charts and M&A subsidiary rollups in the National Institute of Allergy and Infectious Diseases (NIAID) Interactive Dossier, benchmark peers in Infectious Disease and Vaccines, or review the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI